Collplant Biotechnologies

Collplant Biotechnologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Collplant Biotechnologies (CLGN) as of Nov 3, 2026 is 82.23 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.76 % — a change of -6.30% (lower).

FCF Conversion

82.23 %

YoY

-6.30%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Collplant Biotechnologies is 2025 82.23 % . FCF Conversion Rate (FCF/EBITDA) of Collplant Biotechnologies was 2024 87.76 % . It decreases by -6.30% lower compared to the previous year.

The Collplant Biotechnologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
32.79 USD
Jan 1, 2019
64.44 USD
Jan 1, 2020
84.66 USD
Jan 1, 2021
452.74 USD
Jan 1, 2022
88.46 USD
Jan 1, 2023
52.96 USD
Jan 1, 2024
87.76 USD
Jan 1, 2025
82.23 USD
The Collplant Biotechnologies FCF Conversion history
YEARFCF ConversionYoY
82.23 %-6.30%
87.76 %+65.72%
52.96 %-40.14%
88.46 %-80.46%
452.74 %+434.81%
84.66 %+31.37%
64.44 %+96.53%
32.79 %-62.63%
87.74 %+23.74%
70.90 %-16.52%
84.93 %-9.38%
93.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Collplant Biotechnologies Stock analysis

What does Collplant Biotechnologies do? CollPlant Biotechnologies Ltd. develops and markets regenerative medicine products based on plant-derived collagen type I (rhCollagen) for tissue repair and organ bioprinting. The company focuses on medical aesthetics and tissue regeneration applications, targeting healthcare providers and research institutions seeking advanced bioprinting solutions. Its core technology enables the production of collagen without animal sources, addressing market demands for ethical and sustainable biomaterials. The firm's products include bioprinting solutions for tissue and organ production, which are sold to medical research organizations and healthcare facilities. CollPlant's technology differentiates itself through plant-based collagen, appealing to clients prioritizing eco-friendly and animal-free medical solutions. This approach aligns with growing industry trends toward sustainable regenerative medicine practices. CollPlant Biotechnologies Ltd. generates revenue through the sale of its bioprinting technologies and collagen-based medical products. The company's target segments include regenerative medicine researchers, tissue engineering specialists, and medical aesthetics providers who require advanced biomaterials for their applications. These segments value the company's plant-derived collagen technology for its ethical sourcing and performance in tissue repair applications. Collplant Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Collplant Biotechnologies stock

FCF Conversion Rate (FCF/EBITDA) of Collplant Biotechnologies is 82.23 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Collplant Biotechnologies changed from 87.76 % to 82.23 %, representing a -6.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Collplant Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Collplant Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Collplant Biotechnologies

All Key Metrics — Collplant Biotechnologies